Recruiting

Testing a new injection to reduce bleeding in mild to moderate hemophilia

Plain-English translation of NCT07923981 on ClinicalTrials.gov ↗ · Source last updated November 2026 · Translation generated November 2026 · How we translate trials

What is this trial?

This trial is testing , a new medication given as a weekly injection under the skin, to see if it can reduce bleeding episodes in people with mild to moderate hemophilia A or B. Researchers want to compare how often people bleed while taking this medication versus how often they bled with their previous treatment. The study will track participants for up to 4 years to understand both how well the medication works and how safe it is.

Many people with mild to moderate hemophilia still experience serious bleeding despite using standard factor replacement therapy (the traditional treatment). This medication works differently and may offer better protection against bleeds, potentially reducing the burden of frequent treatments.

Do you qualify?

You likely qualify if…

you are between 12 and 74 years old and weigh at least 77 pounds
you have been diagnosed with mild to moderate hemophilia A or B without inhibitors
you have a history of significant bleeding despite receiving treatment over the past year
you have at least 12 months of medical records or bleeding diary documenting your bleeding episodes

You likely don't qualify if…

you have a history of blood clots or a clotting disorder (other than hemophilia)
you have heart disease, a history of stroke, or serious circulation problems
you are currently using other newer hemophilia treatments, gene therapy, or certain blood-thinning medications
you have serious kidney or liver disease, or significant lab abnormalities
you are taking estrogen-based birth control or hormone replacement therapy (there is a 30-day washout period required)

What participation looks like

You would receive an injection of the medication under your skin once per week for 12 months, then have the option to continue for up to 3 additional years. During this time, you'll track any bleeding episodes and attend regular clinic visits so researchers can monitor how well the medication is working and check for any side effects. The study compares your bleeding during this new treatment with your bleeding history from the 12 months before you enrolled.

Testing a new injection to reduce bleeding in mild to moderate hemophilia

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)